Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diseases of the Thyroid

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 20 articles:
HTML format
Text format



Single Articles


    April 2018
  1. THAKUR S, Daley B, Gaskins K, Vasko VV, et al
    Metformin targets Mitochondrial Glycerophosphate Dehydrogenase (mGPDH) to control Rate of Oxidative Phosphorylation and growth of thyroid cancer in vitro and in vivo.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-17-3167.
    PubMed     Text format     Abstract available


  2. POZDEYEV N, Gay L, Sokol ES, Hartmaier RJ, et al
    Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0373.
    PubMed     Text format     Abstract available


    January 2018
  3. HANNA GJ, Busaidy NL, Chau NG, Wirth LJ, et al
    Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2297.
    PubMed     Text format     Abstract available


    November 2017
  4. KRAFT IL, Akshintala S, Zhu YJ, Lei H, et al
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Clin Cancer Res. 2017 Nov 29. pii: 1078-0432.CCR-17-2101.
    PubMed     Text format     Abstract available


    October 2017
  5. MIN IM, Shevlin E, Vedvyas Y, Zaman M, et al
    CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors.
    Clin Cancer Res. 2017 Oct 12. pii: clincanres.2008.2017.
    PubMed     Text format     Abstract available


    June 2017
  6. IBRAHIMPASIC T, Xu B, Landa I, Dogan S, et al
    Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence.
    Clin Cancer Res. 2017 Jun 20. pii: clincanres.1183.2017.
    PubMed     Text format     Abstract available


  7. KOTIAN S, Zhang L, Boufraqech M, Gaskins K, et al
    Dual Inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.1043.2017.
    PubMed     Text format     Abstract available


    October 2016
  8. GIBSON WJ, Ruan DT, Paulson VA, Barletta JA, et al
    Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer.
    Clin Cancer Res. 2016 Oct 17. pii: clincanres.2154.2016.
    PubMed     Text format     Abstract available


  9. RAUE F, Frank-Raue K
    Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Clin Cancer Res. 2016;22:5012-5021.
    PubMed     Text format     Abstract available


    September 2016
  10. MANCIKOVA V, Montero-Conde C, Perales-Paton J, Fernandez AF, et al
    Multilayer OMIC data in medullary thyroid carcinoma identifies the STAT3 pathway as a potential therapeutic target in RETM918T tumors.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0947.2016.
    PubMed     Text format     Abstract available


    July 2016
  11. ZHU X, Enomoto K, Zhao L, Zhu YJ, et al
    Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse model.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0914.2016.
    PubMed     Text format     Abstract available


    June 2016
  12. ABDULGHANI J, Gokare P, Gallant JN, Dicker DT, et al
    Sorafenib and quinacrine target anti-apoptotic protein Mcl-1: a poor prognostic marker in anaplastic thyroid cancer (ATC).
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.2792.2015.
    PubMed     Text format     Abstract available


    February 2016
  13. YU XM, Jaskula-Sztul R, Georgen MR, Aburjania Z, et al
    Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression.
    Clin Cancer Res. 2016 Feb 4. pii: clincanres.1749.2015.
    PubMed     Text format     Abstract available


    December 2015
  14. ROTHENBERG SM, Daniels GH, Wirth LJ
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.
    Clin Cancer Res. 2015;21:5640-5641.
    PubMed     Text format    


  15. HUILLARD O, Tenenbaum F, Clerc J, Goldwasser F, et al
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Letter.
    Clin Cancer Res. 2015;21:5639.
    PubMed     Text format    


    October 2015
  16. SWIERNIAK M, Wojcicka A, Czetwertynska M, Dlugosinska J, et al
    Association Between GWAS-derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1746.2015.
    PubMed     Text format     Abstract available


  17. YEUNG KT, Cohen EE
    Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
    Clin Cancer Res. 2015 Oct 20. pii: clincanres.0923.2015.
    PubMed     Text format     Abstract available


  18. FREEMAN-KELLER M, Kim Y, Cronin H, Richards A, et al
    Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
    Clin Cancer Res. 2015 Oct 7. pii: clincanres.1136.2015.
    PubMed     Text format     Abstract available


    August 2015
  19. NAIR A, Lemery SJ, Yang J, Marathe A, et al
    FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Aug 31. pii: clincanres.1377.2015.
    PubMed     Text format     Abstract available


  20. SCHLUMBERGER M, Jarzab B, Cabanillas ME, Robinson BG, et al
    A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC).
    Clin Cancer Res. 2015 Aug 26. pii: clincanres.1127.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diseases of the Thyroid is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: